Professor Maha Hussain

2023 Maha Hussain Trustee

Professor Maha Hussain is the Genevieve Teuton Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine, and the Deputy Director, and leader of the GU Oncology Program at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine in Chicago.

Maha is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology, particularly prostate and bladder cancer. Her research is focused on the development of novel therapeutics integrating scientific advances into clinical trials and has contributed to significantly impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer.

Prior to joining the Northwestern University faculty Maha was a tenured Professor, Departments of Internal Medicine and Urology, at the University of Michigan .

Maha has served in a variety of national scientific leadership roles in the USA in the fields of prostate cancer and oncology, including serving including the Chair of the SWOG Advanced Prostate Cancer Subcommittee (1994-2012), and a member (2004-2008) and Chair (2007- 2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee and as a member of the US National Cancer Institute (NCI) Cancer Biomarker Study Section and the NCI’s Prostate cancer task force.

Maha is the author/coauthor of more than 300 scholarly articles and book chapters, and has been invited to give hundreds of lectures on her work in the United States and many countries around the world.

Maha has received many honors and awards, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO in 2010. She has been named for many years in America’s Top Doctors” and “America´s Top Doctors for Cancer and since 2017 she was named Castle Connolly Exceptional Women in Medicine. In 2015 she was named one of OncLive’s Giants of Cancer Care.